PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24128813-7	2013	Overall, the data support a binding site for palonosetron at the classic orthosteric binding pocket between two 5-HT3A receptor subunits but not at allosteric sites previously identified by in silico modelling and docking.	Palonosetron	45-57	5-hydroxytryptamine receptor 3A	Homo sapiens	112-118	
33419241-6	2020	Palonosetron, a serotonin type 3 receptor (5-hydroxytryptamine receptor 3 (5-HT3R)) antagonist, was identified by both CLUE and FAERS analyses.	Palonosetron	0-12	5-hydroxytryptamine receptor 3A	Homo sapiens	75-81	
15830306-11	2005	Palonosetron is a new drug in the class of 5-HT (3) (serotonin) receptor antagonists.	Palonosetron	0-12	5-hydroxytryptamine receptor 3A	Homo sapiens	43-72	
23115686-2	2012	Palonosetron, the newest 5-HT3 antagonist, has potent antiemetic property.	Palonosetron	0-12	5-hydroxytryptamine receptor 3A	Homo sapiens	25-30	
20724042-2	2010	With respect to the many other drugs already in use, such as the first generation 5-HT(3)R antagonist granisetron, palonosetron, a second generation antagonist, clearly demonstrates superior inhibition potency towards the 5-HT(3)Rs.	Palonosetron	115-127	5-hydroxytryptamine receptor 3A	Homo sapiens	82-90	
20724042-6	2010	The results of docking studies of the natural agonist serotonin and the antagonists palonosetron and granisetron into the modelled homomeric and heteromeric 5-HT(3)R binding interfaces, provide a possible rationalization both of the higher potency of palonosetron with respect to other antagonists, and of its previously reported allosteric binding and positive cooperativity properties.	Palonosetron	84-96	5-hydroxytryptamine receptor 3A	Homo sapiens	157-165	
20724042-6	2010	The results of docking studies of the natural agonist serotonin and the antagonists palonosetron and granisetron into the modelled homomeric and heteromeric 5-HT(3)R binding interfaces, provide a possible rationalization both of the higher potency of palonosetron with respect to other antagonists, and of its previously reported allosteric binding and positive cooperativity properties.	Palonosetron	251-263	5-hydroxytryptamine receptor 3A	Homo sapiens	157-165	
14760130-2	2004	Palonosetron, a potent and highly selective 5-HT3 antagonist with a strong affinity for 5-HT3 and a prolonged plasma elimination half-life, may provide a longer duration of action than other approved agents.	Palonosetron	0-12	5-hydroxytryptamine receptor 3A	Homo sapiens	44-49	
14760130-2	2004	Palonosetron, a potent and highly selective 5-HT3 antagonist with a strong affinity for 5-HT3 and a prolonged plasma elimination half-life, may provide a longer duration of action than other approved agents.	Palonosetron	0-12	5-hydroxytryptamine receptor 3A	Homo sapiens	88-93